查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1621586

疫苗契約製造市場：按類型、功能和應用分類 - 2025-2030 年全球預測

Vaccine Contract Manufacturing Market by Type (Attenuated Vaccine, DNA Vaccines, Inactivated Vaccine), Function (Downstream, Upstream), Application - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年疫苗契約製造市場的市場規模為50.6億美元，預計2024年將達到55.1億美元，複合年成長率為9.21%，預計到2030年將達到93.9億美元。

疫苗契約製造市場主要涉及將疫苗生產流程外包給具有大規模生產、合規性和先進技術平台支援專業能力的第三方製造商。隨著全球健康挑戰的加劇，包括新興感染疾病的出現和快速部署疫苗的需要，這個領域變得越來越重要。對疫苗契約製造的需求源於對疫苗不斷成長的需求，特別是在大流行期間，速度和產能是關鍵瓶頸。應用涵蓋多種治療領域，包括感染疾病預防性疫苗、腫瘤學以及 mRNA 技術等創新方法。該領域的最終用戶主要是製藥公司、醫療保健提供者和政府機構。

主要市場統計
基準年[2023] 50.6億美元
預測年份 [2024] 55.1億美元
預測年份 [2030] 93.9億美元
複合年成長率（%） 9.21%

市場成長受到多種因素的推動，例如藥品供應鏈的全球化、疫苗製造方法的技術進步以及醫療保健支出的增加。此外，人們對疾病預防意識的增強以及對流行病和大流行病防備的重視也推動了需求。機會存在於正在大力投資醫療基礎設施和核酸疫苗等新型疫苗技術的新興市場。積極與生物技術公司合作並增加對靈活製造技術的投資可以提供競爭優勢。然而，嚴格的法規環境、高昂的初始資本投資以及疫苗生產中基因改造生物的道德擔憂等挑戰可能會阻礙成長。

對自動化和生物程序創新的投資是潛在成長的領域。此外，還應優先研究改善低溫運輸物流以及提高疫苗功效和安全性。該市場的特點是技術快速進步以及公司之間旨在發揮集體優勢的聯盟。為了抓住潛在機遇，企業應專注於策略聯盟、橫向擴張以實現能力多元化，並集中投資研發以推動創新。因此，了解監管環境並開發適合每個市場的業務對於在這個動態環境中實現永續成長和獲得競爭優勢至關重要。

市場動態：揭示快速發展的疫苗契約製造市場的關鍵市場洞察

疫苗契約製造市場正在因供需的動態相互作用而發生轉變。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助企業了解消費行為及其對製造業的影響。

  • 市場促進因素
    • 疫苗需求增加導致契約製造產能增加
    • 委託製造帶來的成本和時間節省的主要優勢
    • 全球疫苗接種覆蓋率
  • 市場限制因素
    • 對成熟疫苗製造商外包的限制
  • 市場機會
    • 全球需求不斷成長，以滿足不斷成長的各年齡層人口的需求
    • 創新和強大的疫苗研發管線
    • 政府對加快疫苗生產的有利見解和指導方針
  • 市場挑戰
    • 製藥公司正在將製造業務納入內部，以獲得策略控制權。

波特五力：駕馭疫苗契約製造市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解疫苗契約製造市場的外部影響

外部宏觀環境因素在塑造疫苗契約製造市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解疫苗契約製造市場的競爭狀況

疫苗契約製造市場的詳細市場佔有率分析提供了對供應商績效的全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV定位矩陣疫苗契約製造市場供應商績效評估

FPNV定位矩陣是評估疫苗契約製造市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議繪製疫苗契約製造市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對疫苗契約製造市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開發：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、未開發地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點關注可望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 疫苗需求增加擴大了契約製造的產能
      • 合約服務的主要好處包括節省成本和時間
      • 世界各地的疫苗接種率
    • 抑制因素
      • 老牌疫苗製造商的外包有限
    • 機會
      • 全球需求不斷成長，以滿足不斷成長的不同年齡層人口的需求
      • 創新和強大的疫苗產品線
      • 政府對加速疫苗生產的有利觀點和指導方針
    • 任務
      • 製藥公司在內部進行生產業務以獲得策略控制
  • 市場區隔分析
    • 類型：更多採用減毒疫苗來增強免疫力
    • 特點：增加下游加工配方的使用，包括生物產品精製和配方
    • 應用：契約製造人用疫苗以保護人們免受感染疾病的潛力不斷成長
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章 疫苗契約製造市場：依類型

  • 減毒疫苗
  • DNA疫苗
  • 去活化疫苗
  • 次單位疫苗
  • 類毒素疫苗

第7章 疫苗契約製造市場：依功能分類

  • 下游
    • 分析和品管研究
    • 填充和整理操作
    • 包裹
  • 上游
    • 細菌表現系統
    • 桿狀病毒或昆蟲表現系統
    • 哺乳動物表達系統
    • 酵母表現系統

第8章疫苗契約製造市場：依應用分類

  • 人類使用
  • 獸醫

第9章 北美和南美疫苗契約製造市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太疫苗契約製造市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章 歐洲、中東和非洲疫苗契約製造市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭場景分析
    • Vaxcyte 和 Lonza 擴大頻譜肺炎鏈球菌結合疫苗 (PCV) 的全球商業生產合作
    • 牛津大學以 1500 萬歐元從梅里埃研究所收購 ABL Europe
    • 輝瑞與三星生物製品公司簽署價值 1.83 億美元的契約製造協議
  • 戰略分析和建議

公司名單

  • AbbVie Inc
  • Ajinomoto Bio-Pharma Services by Ajinomoto Co., Inc.
  • Aton（Shanghai）Biotech Co., Ltd.
  • Avid Bioservices, Inc.
  • Catalent, Inc.
  • Charles River Laboratories International, Inc.
  • CSL Limited
  • Curia Global, Inc.
  • Cytovance Biologics by Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
  • Emergent BioSolutions Inc.
  • FUJIFILM Diosynth Biotechnologies USA, Inc. by FUJIFILM Corporation
  • Gedeon Richter PLC
  • GlaxoSmithKline PLC
  • ICON PLC
  • IDT Biologika GmbH
  • KBI Biopharma, Inc. by JSR Corporation
  • Klocke Pharma-Service GmbH
  • Lonza Group Ltd.
  • Merck KGaA
  • Moderna, Inc.
  • Pfizer Inc.
  • Pharmaceutical Product Development by Thermo Fisher Scientific Inc.
  • Recipharm AB
  • Serum Institute of India
  • Vetter Pharma-Fertigung GmbH & Co. KG
Product Code: MRR-430D42AA0DC4

The Vaccine Contract Manufacturing Market was valued at USD 5.06 billion in 2023, expected to reach USD 5.51 billion in 2024, and is projected to grow at a CAGR of 9.21%, to USD 9.39 billion by 2030.

The Vaccine Contract Manufacturing market primarily involves the outsourcing of vaccine production processes to third-party manufacturers who hold specialized capabilities in handling large-scale production, regulatory compliance, and advanced technology platforms. This sector is increasingly crucial due to escalating global health challenges, which include the emergence of new infectious diseases and the need for rapid vaccine deployment. The necessity of vaccine contract manufacturing arises from the growing demand for vaccines, especially during pandemics, where speed and capacity become critical bottlenecks. Applications span across various therapeutic areas including preventative vaccines for infectious diseases, oncology, and through innovative modalities like mRNA technology. End-users in this realm primarily include pharmaceutical companies, healthcare providers, and government agencies.

KEY MARKET STATISTICS
Base Year [2023] USD 5.06 billion
Estimated Year [2024] USD 5.51 billion
Forecast Year [2030] USD 9.39 billion
CAGR (%) 9.21%

Market growth is propelled by several factors, including the globalization of pharmaceutical supply chains, technological advancements in vaccine production methods, and increasing healthcare expenditure. Moreover, the rise in awareness regarding disease prevention and the emphasis on endemic and pandemic preparedness also fuel demand. Opportunities lie in emerging markets that are investing heavily in healthcare infrastructure and in novel vaccine technologies such as nucleic acid vaccines. Venturing into partnerships with biotech firms and increasing investments in flexible manufacturing technology could provide competitive advantages. However, challenges such as stringent regulatory environments, high initial capital investments, and ethical concerns over genetically modified organisms in vaccine production can impede growth.

Investment in automation and bioprocessing innovations represents potential areas for growth. Additionally, research into improving cold chain logistics and enhancing vaccine efficacy and safety profiles should be prioritized. The market is typified by rapid technological advancements and partnerships between entities aiming to leverage collective strengths. To seize potential opportunities, firms should focus on strategic alliances, horizontal expansion to diversify capabilities, and heavy investment in R&D to propel innovation. Hence, understanding regulatory landscapes and tailoring operations for each market are vital for sustained growth and competitive advantage in this dynamic landscape.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Vaccine Contract Manufacturing Market

The Vaccine Contract Manufacturing Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing demand for vaccines leading to capacity expansion by contract manufacturers
    • Key advantages such as cost and time saving offered by contract services
    • Vaccination coverage across the globe
  • Market Restraints
    • Limited outsourcing by well-established vaccine manufacturers
  • Market Opportunities
    • Rising global demand to cater to the growing population of varied age groups
    • Innovation and robust vaccine pipeline
    • Favorable government insights and guidelines to speed up the vaccine manufacturing
  • Market Challenges
    • Pharma companies manufacturing operations in-house to gain strategic control

Porter's Five Forces: A Strategic Tool for Navigating the Vaccine Contract Manufacturing Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Vaccine Contract Manufacturing Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Vaccine Contract Manufacturing Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Vaccine Contract Manufacturing Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Vaccine Contract Manufacturing Market

A detailed market share analysis in the Vaccine Contract Manufacturing Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Vaccine Contract Manufacturing Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Vaccine Contract Manufacturing Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Vaccine Contract Manufacturing Market

A strategic analysis of the Vaccine Contract Manufacturing Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Vaccine Contract Manufacturing Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc, Ajinomoto Bio-Pharma Services by Ajinomoto Co., Inc., Aton (Shanghai) Biotech Co., Ltd., Avid Bioservices, Inc., Catalent, Inc., Charles River Laboratories International, Inc., CSL Limited, Curia Global, Inc., Cytovance Biologics by Shenzhen Hepalink Pharmaceutical Group Co., Ltd., Emergent BioSolutions Inc., FUJIFILM Diosynth Biotechnologies U.S.A., Inc. by FUJIFILM Corporation, Gedeon Richter PLC, GlaxoSmithKline PLC, ICON PLC, IDT Biologika GmbH, KBI Biopharma, Inc. by JSR Corporation, Klocke Pharma-Service GmbH, Lonza Group Ltd., Merck KGaA, Moderna, Inc., Pfizer Inc., Pharmaceutical Product Development by Thermo Fisher Scientific Inc., Recipharm AB, Serum Institute of India, and Vetter Pharma-Fertigung GmbH & Co. KG.

Market Segmentation & Coverage

This research report categorizes the Vaccine Contract Manufacturing Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Attenuated Vaccine, DNA Vaccines, Inactivated Vaccine, Subunit Vaccines, and Toxoid Vaccines.
  • Based on Function, market is studied across Downstream and Upstream. The Downstream is further studied across Analytical & QC studies, Fill & Finish Operations, and Packaging. The Upstream is further studied across Bacterial Expression Systems, Baculovirus or Insect Expression Systems, Mammalian Expression Systems, and Yeast Expression Systems.
  • Based on Application, market is studied across Human Use and Veterinary.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing demand for vaccines leading to capacity expansion by contract manufacturers
      • 5.1.1.2. Key advantages such as cost and time saving offered by contract services
      • 5.1.1.3. Vaccination coverage across the globe
    • 5.1.2. Restraints
      • 5.1.2.1. Limited outsourcing by well-established vaccine manufacturers
    • 5.1.3. Opportunities
      • 5.1.3.1. Rising global demand to cater to the growing population of varied age groups
      • 5.1.3.2. Innovation and robust vaccine pipeline
      • 5.1.3.3. Favorable government insights and guidelines to speed up the vaccine manufacturing
    • 5.1.4. Challenges
      • 5.1.4.1. Pharma companies manufacturing operations in-house to gain strategic control
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Growing adoption of attenuated vaccines to enhance immune systems
    • 5.2.2. Function: Increasing usage of downstream processing formulations that involve the purification and formulation of the bioproducts
    • 5.2.3. Application: Rising potential of vaccine contract manufacturing for human use to protect populations against infectious diseases
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Vaccine Contract Manufacturing Market, by Type

  • 6.1. Introduction
  • 6.2. Attenuated Vaccine
  • 6.3. DNA Vaccines
  • 6.4. Inactivated Vaccine
  • 6.5. Subunit Vaccines
  • 6.6. Toxoid Vaccines

7. Vaccine Contract Manufacturing Market, by Function

  • 7.1. Introduction
  • 7.2. Downstream
    • 7.2.1. Analytical & QC studies
    • 7.2.2. Fill & Finish Operations
    • 7.2.3. Packaging
  • 7.3. Upstream
    • 7.3.1. Bacterial Expression Systems
    • 7.3.2. Baculovirus or Insect Expression Systems
    • 7.3.3. Mammalian Expression Systems
    • 7.3.4. Yeast Expression Systems

8. Vaccine Contract Manufacturing Market, by Application

  • 8.1. Introduction
  • 8.2. Human Use
  • 8.3. Veterinary

9. Americas Vaccine Contract Manufacturing Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Vaccine Contract Manufacturing Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Vaccine Contract Manufacturing Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Vaxcyte and Lonza Expand Collaboration for Global Commercial Manufacturing of Broad-Spectrum Pneumococcal Conjugate Vaccines (PCVs)
    • 12.3.2. Oxford Acquires ABL Europe From Institut Merieux For EUR 15 Mn
    • 12.3.3. Pfizer Inks USD 183M Contract Manufacturing Deal With Samsung Biologics
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc
  • 2. Ajinomoto Bio-Pharma Services by Ajinomoto Co., Inc.
  • 3. Aton (Shanghai) Biotech Co., Ltd.
  • 4. Avid Bioservices, Inc.
  • 5. Catalent, Inc.
  • 6. Charles River Laboratories International, Inc.
  • 7. CSL Limited
  • 8. Curia Global, Inc.
  • 9. Cytovance Biologics by Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
  • 10. Emergent BioSolutions Inc.
  • 11. FUJIFILM Diosynth Biotechnologies U.S.A., Inc. by FUJIFILM Corporation
  • 12. Gedeon Richter PLC
  • 13. GlaxoSmithKline PLC
  • 14. ICON PLC
  • 15. IDT Biologika GmbH
  • 16. KBI Biopharma, Inc. by JSR Corporation
  • 17. Klocke Pharma-Service GmbH
  • 18. Lonza Group Ltd.
  • 19. Merck KGaA
  • 20. Moderna, Inc.
  • 21. Pfizer Inc.
  • 22. Pharmaceutical Product Development by Thermo Fisher Scientific Inc.
  • 23. Recipharm AB
  • 24. Serum Institute of India
  • 25. Vetter Pharma-Fertigung GmbH & Co. KG

LIST OF FIGURES

  • FIGURE 1. VACCINE CONTRACT MANUFACTURING MARKET RESEARCH PROCESS
  • FIGURE 2. VACCINE CONTRACT MANUFACTURING MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. VACCINE CONTRACT MANUFACTURING MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. VACCINE CONTRACT MANUFACTURING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. VACCINE CONTRACT MANUFACTURING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. VACCINE CONTRACT MANUFACTURING MARKET DYNAMICS
  • TABLE 7. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY ATTENUATED VACCINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DNA VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY INACTIVATED VACCINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SUBUNIT VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TOXOID VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL & QC STUDIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FILL & FINISH OPERATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY PACKAGING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY BACTERIAL EXPRESSION SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY BACULOVIRUS OR INSECT EXPRESSION SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY MAMMALIAN EXPRESSION SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY YEAST EXPRESSION SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY HUMAN USE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VETERINARY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 43. BRAZIL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 46. CANADA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 47. CANADA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 48. CANADA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 49. MEXICO VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. MEXICO VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 51. MEXICO VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 52. MEXICO VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 53. MEXICO VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 54. UNITED STATES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 58. UNITED STATES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 59. UNITED STATES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 65. ASIA-PACIFIC VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 66. AUSTRALIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. AUSTRALIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 68. AUSTRALIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 69. AUSTRALIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 70. AUSTRALIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 71. CHINA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. CHINA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 73. CHINA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 74. CHINA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 75. CHINA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 76. INDIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. INDIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 78. INDIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 79. INDIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 80. INDIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 81. INDONESIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. INDONESIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 83. INDONESIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 84. INDONESIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 85. INDONESIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 86. JAPAN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. JAPAN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 88. JAPAN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 89. JAPAN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 90. JAPAN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 91. MALAYSIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. MALAYSIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 93. MALAYSIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 94. MALAYSIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 95. MALAYSIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 96. PHILIPPINES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. PHILIPPINES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 98. PHILIPPINES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 99. PHILIPPINES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 100. PHILIPPINES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 101. SINGAPORE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. SINGAPORE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 103. SINGAPORE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 104. SINGAPORE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 105. SINGAPORE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 106. SOUTH KOREA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. SOUTH KOREA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 108. SOUTH KOREA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 109. SOUTH KOREA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 110. SOUTH KOREA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 111. TAIWAN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. TAIWAN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 113. TAIWAN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 114. TAIWAN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 115. TAIWAN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 116. THAILAND VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. THAILAND VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 118. THAILAND VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 119. THAILAND VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 120. THAILAND VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 121. VIETNAM VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. VIETNAM VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 123. VIETNAM VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 124. VIETNAM VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 125. VIETNAM VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 132. DENMARK VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. DENMARK VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 134. DENMARK VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 135. DENMARK VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 136. DENMARK VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 137. EGYPT VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. EGYPT VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 139. EGYPT VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 140. EGYPT VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 141. EGYPT VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 142. FINLAND VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. FINLAND VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 144. FINLAND VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 145. FINLAND VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 146. FINLAND VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 147. FRANCE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. FRANCE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 149. FRANCE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 150. FRANCE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 151. FRANCE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 152. GERMANY VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. GERMANY VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 154. GERMANY VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 155. GERMANY VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 156. GERMANY VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 157. ISRAEL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. ISRAEL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 159. ISRAEL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 160. ISRAEL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 161. ISRAEL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 162. ITALY VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. ITALY VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 164. ITALY VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 165. ITALY VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 166. ITALY VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 167. NETHERLANDS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. NETHERLANDS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 169. NETHERLANDS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 170. NETHERLANDS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 171. NETHERLANDS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 172. NIGERIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. NIGERIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 174. NIGERIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 175. NIGERIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 176. NIGERIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 177. NORWAY VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. NORWAY VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 179. NORWAY VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 180. NORWAY VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 181. NORWAY VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 182. POLAND VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. POLAND VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 184. POLAND VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 185. POLAND VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 186. POLAND VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 187. QATAR VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. QATAR VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 189. QATAR VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 190. QATAR VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 191. QATAR VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 192. RUSSIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 193. RUSSIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 194. RUSSIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 195. RUSSIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 196. RUSSIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 197. SAUDI ARABIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 198. SAUDI ARABIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 199. SAUDI ARABIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 200. SAUDI ARABIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 201. SAUDI ARABIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 202. SOUTH AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 204. SOUTH AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 205. SOUTH AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 206. SOUTH AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 207. SPAIN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 208. SPAIN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 209. SPAIN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 210. SPAIN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 211. SPAIN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 212. SWEDEN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 213. SWEDEN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 214. SWEDEN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 215. SWEDEN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 216. SWEDEN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 217. SWITZERLAND VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 218. SWITZERLAND VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 219. SWITZERLAND VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 220. SWITZERLAND VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 221. SWITZERLAND VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 222. TURKEY VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 223. TURKEY VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 224. TURKEY VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 225. TURKEY VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 226. TURKEY VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 227. UNITED ARAB EMIRATES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED ARAB EMIRATES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED ARAB EMIRATES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED ARAB EMIRATES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED ARAB EMIRATES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED KINGDOM VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED KINGDOM VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED KINGDOM VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED KINGDOM VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 236. UNITED KINGDOM VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 237. VACCINE CONTRACT MANUFACTURING MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 238. VACCINE CONTRACT MANUFACTURING MARKET, FPNV POSITIONING MATRIX, 2023